Compiling results from six previous studies, the analysis found Vectra DA scores are associated with worsening disease but didn't address clinical utility.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.
